## Sarah S Donaldson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1017233/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease. Journal of Clinical Oncology, 2001, 19, 3091-3102.	1.6	962
2	The intergroup rhabdomyosarcoma study-II. Cancer, 1993, 71, 1904-1922.	4.1	547
3	Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV. Journal of Clinical Oncology, 2003, 21, 78-84.	1.6	419
4	Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. Journal of Clinical Oncology, 2009, 27, 5182-5188.	1.6	320
5	The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma, 2001, 5, 9-15.	1.3	246
6	Rhabdomyosarcoma of head and neck in children. Cancer, 1973, 31, 26-35.	4.1	235
7	Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer, 1984, 53, 878-883.	4.1	226
8	Advances Toward an Understanding of Brainstem Gliomas. Journal of Clinical Oncology, 2006, 24, 1266-1272.	1.6	219
9	Epithelioid granulomas associated with Hodgkin's disease.Clinical correlations in 55 previously untreated patients. Cancer, 1978, 41, 562-567.	4.1	210
10	Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcomaâ€"a report from the IRSG 1 1For a complete list of the members of the Children's Oncology Group Soft Tissue Sarcoma Committee (formerly Intergroup Rhabdomyosarcoma Group) representing the Children's Oncology Group and the Quality Assurance Review Center, see the Appendix Intergroup Intergroup Physics 2001, 51, 718-728	0.8	200
11	Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. Journal of Clinical Oncology, 2007, 25, 362-369.	1.6	190
12	Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncology, The, 2018, 19, 1590-1601.	10.7	179
13	Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. , 1999, 33, 362-371.		167
14	Alterations of nutritional status.Impact of chemotherapy and radiation therapy. Cancer, 1979, 43, 2036-2052.	4.1	154
15	Indications for Radiotherapy and Chemotherapy After Complete Resection in Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Studies I to III. Journal of Clinical Oncology, 1999, 17, 3468-3475.	1.6	152
16	What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?. Cancer, 2001, 91, 2454-2468.	4.1	135
17	Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's Disease. Journal of Clinical Oncology, 2007, 25, 332-337.	1.6	125
18	Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkinapos;s disease. Cancer, 1976, 38, 2263-2268.	4.1	124

#	Article	IF	CITATIONS
19	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2018, 36, 2770-2777.	1.6	124
20	Controversies in the Management of Paratesticular Rhabdomyosarcoma: Is Staging Retroperitoneal Lymph Node Dissection Necessary for Adolescents With Resected Paratesticular Rhabdomyosarcoma?. Seminars in Pediatric Surgery, 2001, 10, 146-152.	1.1	121
21	Primary radiotherapy for localized orbital MALT lymphoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 657-663.	0.8	119
22	VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin's Disease: Results of a Prospective Clinical Trial. Journal of Clinical Oncology, 2002, 20, 3081-3087.	1.6	116
23	Reviews: Special Nutritional Needs of Children with Malignancies: A Review. Journal of Parenteral and Enteral Nutrition, 1990, 14, 315-324.	2.6	115
24	Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects. International Journal of Radiation Oncology Biology Physics, 2016, 94, 800-807.	0.8	107
25	Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2011, 29, 1304-1311.	1.6	102
26	Radiotherapy is successful treatment for orbital lymphoma. International Journal of Radiation Oncology Biology Physics, 1993, 26, 59-66.	0.8	98
27	Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma. International Journal of Radiation Oncology Biology Physics, 2013, 86, 930-935.	0.8	96
28	Primary and metastatic rhabdomyosarcoma in the breast: Neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study. , 1997, 29, 181-189.		94
29	Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiotherapy and Oncology, 2014, 113, 89-94.	0.6	93
30	Bacterial infections in pediatric Hodgkin's disease.Relationship to radiotherapy, chemotherapy and splenectomy. Cancer, 1978, 41, 1949-1958.	4.1	91
31	Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin Lymphoma. JAMA - Journal of the American Medical Association, 2012, 307, 2609-16.	7.4	91
32	Ewing sarcoma: Radiation dose and target volume. Pediatric Blood and Cancer, 2004, 42, 471-476.	1.5	87
33	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices. Journal of Clinical Oncology, 2004, 22, 4532-4540.	1.6	85
34	Herpes zoster and varicella infections in children with hodgkin's disease.An analysis of contributing factors. Cancer, 1978, 41, 95-99.	4.1	83
35	Radiation induced height impairment in pediatric Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1994, 28, 85-92.	0.8	82
36	Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 57, 76-83.	1.5	74

#	Article	IF	CITATIONS
37	Treatment of Unfavorable Childhood Hodgkin's Disease With VEPA and Low-Dose, Involved-Field Radiation. Journal of Clinical Oncology, 2002, 20, 3088-3094.	1.6	73
38	Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease. Journal of Clinical Oncology, 2004, 22, 4541-4550.	1.6	73
39	Radiotherapy of lymphoid diseases of the orbit. International Journal of Radiation Oncology Biology Physics, 1985, 11, 371-379.	0.8	71
40	Non-Hodgkin's lymphomas. VI. Results of treatment in childhood. Cancer, 1974, 34, 204-211.	4.1	66
41	Effect of Radiotherapy Techniques (IMRT vs. 3D-CRT) on Outcome in Patients With Intermediate-Risk Rhabdomyosarcoma Enrolled in COG D9803—A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1764-1770.	0.8	61
42	A prospective randomized clinical trial of total parenteral nutrition in children with cancer. Medical and Pediatric Oncology, 1982, 10, 129-139.	1.0	60
43	Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve Outcome. Clinical Cancer Research, 2004, 10, 6072-6079.	7.0	60
44	Nutritional Support as an Adjunct to Radiation Therapy. Journal of Parenteral and Enteral Nutrition, 1984, 8, 302-310.	2.6	57
45	Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. , 1997, 79, 2435-2439.		56
46	The value of adjuvant chemotherapy in the management of sarcomas in children. Cancer, 1985, 55, 2184-2197.	4.1	55
47	Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: AÂReport From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1071-1076.	0.8	55
48	Increased local failure for patients with intermediateâ€risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Cancer, 2019, 125, 3242-3248.	4.1	55
49	Delayed primary excision with subsequent modification of radiotherapy dose for intermediateâ€risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. International Journal of Cancer, 2015, 137, 204-211.	5.1	50
50	Longitudinal followâ€up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. Cancer, 2017, 123, 2551-2560.	4.1	47
51	A Feasibility, Toxicity, and Early Response Study of Etoposide, Ifosfamide, and Vincristine for the Treatment of Children with Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Study (IRS) IV Pilot Study. The American Journal of Pediatric Hematology/oncology, 1997, 19, 124-129.	1.3	46
52	Influence of Noncompliance With Radiation Therapy Protocol Guidelines and Operative Bed Recurrences for Children With Rhabdomyosarcoma and Microscopic Residual Disease: A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2011, 80, 333-338	0.8	42
53	Regional Nodal Involvement and Patterns of Spread Along In-Transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1151-1157.	0.8	39
54	An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatric Blood and Cancer, 2022, 69, e29511.	1.5	37

#	Article	IF	CITATIONS
55	Continuing Medical Student Education During the Coronavirus Disease 2019 (COVID-19) Pandemic: Development of a Virtual Radiation Oncology Clerkship. Advances in Radiation Oncology, 2020, 5, 732-736.	1.2	36
56	The Effect of Radiation Timing on Patients With High-Risk Features of Parameningeal Rhabdomyosarcoma: An Analysis of IRS-IV and D9803. International Journal of Radiation Oncology Biology Physics, 2013, 87, 512-516.	0.8	35
57	The Children's Oncology Group Radiation Oncology Discipline: 15ÂYears of Contributions to the Treatment of Childhood Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 860-874.	0.8	34
58	Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2019, 103, 19-27.	0.8	34
59	45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy. Pediatric Blood and Cancer, 2017, 64, e26540.	1.5	33
60	Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. Journal of Clinical Oncology, 2021, 39, 2276-2283.	1.6	31
61	Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. Cancer, 2001, 92, 3135-3146.	4.1	30
62	Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation. Medical and Pediatric Oncology, 2000, 35, 443-445.	1.0	29
63	Survival and Neurocognitive Outcomes After Cranial or Craniospinal Irradiation Plus Total-Body Irradiation Before Stem Cell Transplantation in Pediatric Leukemia Patients With Central Nervous System Involvement. International Journal of Radiation Oncology Biology Physics, 2014, 89, 67-74.	0.8	29
64	Electrophysiologic evidence of subclinical injury to the posterior columns of the human spinal cord after therapeutic radiation. Cancer, 1982, 50, 2815-2819.	4.1	26
65	Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803—A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 4228-4232.	1.6	26
66	Relapse after treatment of pediatric hodgkin lymphoma: Outcome and role of surveillance after end of therapy. Pediatric Blood and Cancer, 2013, 60, 1458-1463.	1.5	25
67	Topography of Childhood Tumors: Pediatric Coding System. Pediatric Hematology and Oncology, 1986, 3, 249-258.	0.8	24
68	Treatment of Pediatric Hodgkin Lymphoma. Current Treatment Options in Oncology, 2008, 9, 81-94.	3.0	23
69	Cost effectiveness and outcome assessment of magnetic resonance imaging in diagnosing cord compression. Cancer, 1995, 75, 2579-2586.	4.1	22
70	Riskâ€based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2019, 125, 2602-2609.	4.1	21
71	Outcomes for pediatric patients with osteosarcoma treated with palliative radiotherapy. Pediatric Blood and Cancer, 2020, 67, e27967.	1.5	21
72	Prognostic features of ewing sarcoma on plain radiograph and computed tomography scan after initial treatment. A pediatric oncology group study (8346). Cancer, 1993, 72, 2503-2510.	4.1	20

#	Article	IF	CITATIONS
73	Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma. Neuro-Oncology, 2018, 20, 1133-1141.	1.2	20
74	Virtual Radiation Oncology Clerkship During the COVID-19 Pandemic and Beyond. International Journal of Radiation Oncology Biology Physics, 2020, 108, 444-451.	0.8	20
75	Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a Single Institution. Biology of Blood and Marrow Transplantation, 2015, 21, 326-334.	2.0	19
76	Initial clinical outcomes of audiovisual-assisted therapeutic ambience in radiation therapy (AVATAR). Practical Radiation Oncology, 2017, 7, 311-318.	2.1	19
77	Recent advances in understanding and managing rhabdomyosarcoma. F1000prime Reports, 2015, 7, 59.	5.9	19
78	Rhabdomyosarcoma. Pediatric Blood and Cancer, 2021, 68, e28254.	1.5	18
79	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatric Blood and Cancer, 2022, 69, e29644.	1.5	18
80	Pediatric Hodgkin's disease—up, up, and beyond. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1-8.	0.8	17
81	Acute nonlymphocytic leukemia developing during the course of Ewing's sarcoma. Medical and Pediatric Oncology, 1984, 12, 194-200.	1.0	16
82	Safety of Intravenous Hyperalimentation in Children with Malignancies: A Cooperative Group Trial. Journal of Parenteral and Enteral Nutrition, 1982, 6, 291-294.	2.6	15
83	Langerhans' cell histiocytosis presenting with the superior vena cava syndrome: A case report. Medical and Pediatric Oncology, 1993, 21, 456-459.	1.0	14
84	The nutritional effects of cancer and its therapy. Nutrition and Cancer, 1980, 2, 22-29.	2.0	12
85	Treatment of Orbital Lymphoid Tumors with Electron Beams. Frontiers of Radiation Therapy and Oncology, 1991, 25, 187-200.	1.4	11
86	A discourse: The 2002 Wataru W. Sutow lecture Hodgkin disease in children?perspectives and progress. Medical and Pediatric Oncology, 2003, 40, 73-81.	1.0	11
87	Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma. Practical Radiation Oncology, 2016, 6, 255-261.	2.1	11
88	Practice patterns and recommendations for pediatric imageâ€guided radiotherapy: A Children's Oncology Group report. Pediatric Blood and Cancer, 2020, 67, e28629.	1.5	11
89	Making choices in the staging of children with Hodgkin's disease. Medical and Pediatric Oncology, 1991, 19, 211-213.	1.0	9
90	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 67-75.	0.8	9

#	Article	IF	CITATIONS
91	Subspecialty training and certification for radiation oncology. Journal of the American College of Radiology, 2004, 1, 488-492.	1.8	8
92	The Parotid Gland is an Underrecognized Organ at Risk for Craniospinal Irradiation. Technology in Cancer Research and Treatment, 2016, 15, 472-479.	1.9	8
93	Impact of Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy (AVATAR) on Anesthesia Use, Payer Charges, and Treatment Time in Pediatric Patients. Practical Radiation Oncology, 2020, 10, e272-e279.	2.1	8
94	Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 821-830.	0.8	8
95	Use of cardiac radiation therapy as bridging therapy to CARâ€T for relapsed pediatric Bâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28870.	1.5	8
96	Editorial: Is involved field irradiation alone optimal therapy for a child with Hodgkin's disease?. Medical and Pediatric Oncology, 1984, 12, 322-324.	1.0	7
97	Neuro-ocular damage in pediatric oncology patients: Predictor of long-term visual disability or tool for limiting toxicity?. Medical and Pediatric Oncology, 1986, 14, 262-270.	1.0	7
98	Extraskeletal Osteosarcoma of the Hand: The Role of Marginal Excision and Adjuvant Radiation Therapy. Hand, 2015, 10, 602-606.	1.2	6
99	Stereotactic body radiotherapy for pediatric hepatocellular carcinoma with central biliary obstruction. Pediatric Blood and Cancer, 2017, 64, e26330.	1.5	6
100	Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience. Journal of Adolescent and Young Adult Oncology, 2020, 9, 166-171.	1.3	6
101	Chemoradiation impairs normal developmental cortical thinning in medulloblastoma. Journal of Neuro-Oncology, 2017, 133, 429-434.	2.9	5
102	Secondary breast angiosarcoma and germ line BRCA mutations: discussion of genetic susceptibility. Journal of Radiation Oncology, 2013, 2, 331-335.	0.7	4
103	Treatment and outcomes in classic Hodgkin lymphoma postâ€ŧransplant lymphoproliferative disorder in children. Pediatric Blood and Cancer, 2019, 66, e27803.	1.5	4
104	New methods for precision radiation therapy exceed biological and clinical knowledge and institutional resources needed for implementation. Medical Physics, 2000, 27, 2477-2479.	3.0	3
105	Primary and metastatic rhabdomyosarcoma in the breast: neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study. Medical and Pediatric Oncology, 1997, 29, 181-189.	1.0	3
106	Ethics in Radiation Oncology and the American Society for Radiation Oncology's Role. International Journal of Radiation Oncology Biology Physics, 2017, 99, 247-249.	0.8	2
107	Multidisciplinary management of newly diagnosed pediatric large cell neuroendocrine carcinoma of the lung causing hemoptysis. Pediatric Blood and Cancer, 2021, 68, e29182.	1.5	2
108	Tribute to Professor Maurice Tubiana. International Journal of Radiation Oncology Biology Physics, 2014, 88, 755-756.	0.8	1

#	Article	IF	CITATIONS
109	Homage to M. Vera Peters, MD. International Journal of Radiation Oncology Biology Physics, 2015, 92, 5-7.	0.8	1
110	Reported missing founding member of the International Society of Paediatric Oncology …found. Pediatric Blood and Cancer, 2017, 64, e26523.	1.5	1
111	Successful use of frameless stereotactic radiosurgery for treatment of recurrent brain metastases in an 18-month-old child. International Journal of Neuroscience, 2019, 129, 1234-1239.	1.6	1
112	Paraneoplastic Neurologic Symptoms in a Pediatric Patient with Hodgkin Lymphoma. Cancer Investigation, 2020, 39, 1-7.	1.3	1
113	Use of Audiovisual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) for Anesthesia Avoidance in a Pediatric Patient With Down Syndrome. Advances in Radiation Oncology, 2021, 6, 100637.	1.2	1
114	Esophageal disease among childhood cancer survivors—A report from the Childhood Cancer Survivors Study. Pediatric Blood and Cancer, 2021, 68, e29043.	1.5	1
115	Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. Cureus, 2018, 10, e3499.	0.5	1
116	ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma Journal of Clinical Oncology, 2022, 40, TPS11591-TPS11591.	1.6	1
117	Successful Treatment with Temozolomide Combined with Chemoradiotherapy and Surgery of a Metastatic Undifferentiated Soft Tissue Sarcoma with Relapse in the Central Nervous System of a Young Adult. Journal of Adolescent and Young Adult Oncology, 2014, 3, 100-103.	1.3	0
118	Reply to Second malignancies in Ewing sarcoma survivors. Cancer, 2017, 123, 4075-4076.	4.1	0
119	Larry Emanuel Kun, March 10, 1946-May 27, 2018. International Journal of Radiation Oncology Biology Physics, 2019, 103, 8-14.	0.8	0
120	Multimodality treatment including whole pleura radiation therapy for DICER1â€associated pediatric pleuropulmonary blastoma. Pediatric Blood and Cancer, 2021, 68, e29004.	1.5	0
121	Risk group accurately predicts outcome in primary extremity non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients <30 years of age: Findings from Children's Oncology Group study ARST0332 Journal of Clinical Oncology, 2018, 36, 10546-10546.	1.6	0
122	Successful Full-term Pregnancies After High-dose Pelvic Radiotherapy for Ewing Sarcoma: A Case Report. Journal of Pediatric Hematology/Oncology, 2020, 42, e807-e809.	0.6	0